HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours.
Cancer
Doxorubicin
Drug delivery
HPMA
Star-like polymers
bisMPA
Journal
Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
26
09
2019
revised:
27
11
2019
accepted:
22
12
2019
pubmed:
12
2
2020
medline:
15
5
2021
entrez:
12
2
2020
Statut:
ppublish
Résumé
Design, controlled synthesis, physico-chemical and biological characteristics of novel well-defined biodegradable star-shaped copolymers intended for advanced drug delivery is described. These new biocompatible star copolymers were synthesised by grafting monodispersed semitelechelic linear (sL) N-(2-hydroxypropyl)methacrylamide copolymers onto a 2,2-bis(hydroxymethyl)propionic acid (bisMPA)-based polyester dendritic core of various structures. The hydrodynamic diameter of the star copolymer biomaterials can be tuned from 13 to 31 nm and could be adjusted to a given purpose by proper selection of the bisMPA dendritic core type and generation and by considering the sL copolymer molecular weight and polymer-to-core molar ratio. The hydrolytic degradation was proved for both the star copolymers containing either dendron or dendrimer core, showing the spontaneous hydrolysis in duration of few weeks. Finally, it was shown that the therapy with the biodegradable star conjugate with attached doxorubicin strongly suppresses the tumour growth in mice and is fully curative in most of the treated animals at dose corresponding approximately to one fourth of maximum tolerated dose (MTD) value. Both new biodegradable systems show superior efficacy and tumour accumulation over the first generation of star copolymers containing non-degradable PAMAM core.
Identifiants
pubmed: 32044514
pii: S0142-9612(19)30846-4
doi: 10.1016/j.biomaterials.2019.119728
pmc: PMC7123463
mid: NIHMS1558552
pii:
doi:
Substances chimiques
Acrylamides
0
Biocompatible Materials
0
Drug Carriers
0
Methacrylates
0
Pharmaceutical Preparations
0
Polymers
0
Doxorubicin
80168379AG
N-(2-hydroxypropyl)methacrylamide
R3F262Z4E0
hydroxypropyl methacrylate
UKW89XAX2X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119728Subventions
Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
J Drug Target. 2011 Dec;19(10):874-89
pubmed: 21978286
Biomacromolecules. 2018 Oct 8;19(10):4003-4013
pubmed: 30180562
J Control Release. 2001 May 18;73(1):89-102
pubmed: 11337062
J Control Release. 2013 Dec 10;172(2):504-12
pubmed: 23697767
J Control Release. 2016 Feb 10;223:1-10
pubmed: 26708020
J Control Release. 2012 Dec 28;164(3):346-54
pubmed: 22759979
Biomaterials. 2012 Mar;33(7):1970-81
pubmed: 22177621
Biomaterials. 2010 Oct;31(30):7797-804
pubmed: 20673684
Adv Mater. 2019 Aug;31(35):e1901586
pubmed: 31259438
J Control Release. 2005 Dec 10;110(1):119-29
pubmed: 16269198
Physiol Res. 2016 Oct 20;65(Suppl 2):S179-S190
pubmed: 27762584
Adv Drug Deliv Rev. 2010 Feb 17;62(2):192-202
pubmed: 20005272
J Control Release. 2012 Dec 10;164(2):138-44
pubmed: 22595146
Biomaterials. 2017 Jan;115:65-80
pubmed: 27886555
Biomaterials. 2018 Sep;178:738-750
pubmed: 29429845
Bioconjug Chem. 2002 Mar-Apr;13(2):206-15
pubmed: 11906257
ACS Appl Mater Interfaces. 2018 Jan 17;10(2):1575-1588
pubmed: 29260844
Nanoscale. 2017 Aug 3;9(30):10906-10918
pubmed: 28731080
Acta Biomater. 2019 Jan 15;84:339-355
pubmed: 30503561
J Control Release. 2001 Jul 6;74(1-3):225-32
pubmed: 11489498
J Control Release. 2011 Sep 25;154(3):241-8
pubmed: 21699933
Eur J Pharm Sci. 2011 Apr 18;42(5):527-39
pubmed: 21392579
Pharm Res. 2003 Oct;20(10):1558-64
pubmed: 14620507
Trends Biotechnol. 2009 Jan;27(1):11-7
pubmed: 19022512
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1117-20
pubmed: 19682516
Chem Rev. 2016 May 11;116(9):5338-431
pubmed: 27109701
Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49
pubmed: 19919846
J Control Release. 2017 Jan 28;246:1-11
pubmed: 27940304
Pharm Res. 2010 Jan;27(1):200-8
pubmed: 19894105
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Target Oncol. 2016 Feb;11(1):101-6
pubmed: 26194363
J Control Release. 2001 Jul 6;74(1-3):147-58
pubmed: 11489491
Curr Med Chem. 2013;20(38):4815-26
pubmed: 24083609
Tumour Biol. 2010 Aug;31(4):233-42
pubmed: 20556593
Mol Pharm. 2010 Aug 2;7(4):1015-26
pubmed: 20518512
Cancer Immunol Immunother. 2007 Jan;56(1):35-47
pubmed: 16636810
J Am Chem Soc. 2015 Jun 3;137(21):6726-9
pubmed: 25963409
Macromol Rapid Commun. 2017 Nov;38(21):
pubmed: 28895248
J Control Release. 2007 Sep 11;122(1):31-8
pubmed: 17631976